Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Matsunoshita, Yukihiro ^a   Ijiri, Kosei ^a   Ishidou, Yasuhiro ^a   Nagano, Satoshi ^a   Yamamoto, Takuya ^a   Nagao, Hiroko ^a   Komiya, Setsuro ^a   Setoguchi, Takao ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; ETOPOSIDE; METHOTREXATE; UROKINASE; UROKINASE RECEPTOR; ANTINEOPLASTIC AGENT; EGR1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOPSY; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPSY; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79251632187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016234     Document Type: Article

References (56)

1. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, et al. (2009) Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14: 397-404.
2. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21: 1574-1580.
3. Patel SJ, Lynch JW, Jr., Johnson T, Carroll RR, Schumacher C, et al. (2002) Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 25: 489-495.
4. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790.
5. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, et al. (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011.
6. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, et al. (2007) Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96: 118-123.
7. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, et al. (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99: 112-128.
8. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, et al. (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67: 356-364.
9. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, et al. (1995) Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 11: 1261-1269.
10. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, et al. (1997) Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72: 102-109.
11. Huang RP, Liu C, Fan Y, Mercola D, Adamson ED (1995) Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 55: 5054-5062.
12. Hotta T, Motoyama T, Watanabe H (1992) Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol Jpn 42: 595-603.
13. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, et al. (2010) The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep 23: 677-684.
14. Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, et al. (2010) Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 9: 5.
15. Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, et al. (2009) Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 101: 2030-2037.
16. de Belle I, Huang RP, Fan Y, Liu C, Mercola D, et al. (1999) p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18: 3633-3642.
17. Liu C, Yao J, Mercola D, Adamson E (2000) The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 275: 20315-20323.
18. Shingu T, Bornstein P (1994) Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem 269: 32551-32557.
19. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501.
20. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, et al. (2002) Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 65: 1123-1132.
21. Ta HT, Dass CR, Choong PF, Dunstan DE (2009) Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28: 247-263.
22. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, et al. (2005) Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41: 2836-2845.
23. Mirabello L, Troisi RJ, Savage SA (2009) International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125: 229-234.
24. Yu J, Zhang SS, Saito K, Williams S, Arimura Y, et al. (2009) PTEN regulation by Akt-EGR1-ARF-PTEN axis. Embo J 28: 21-33.
25. Kim J, Lee YH, Kwon TK, Chang JS, Chung KC, et al. (2006) Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10. Cancer Res 66: 784-793.
26. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D (2006) The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13: 115-124.
27. Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E (2010) Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer 102: 754-764.
28. Chen CC, Lee WR, Safe S (2004) Egr-1 is activated by 17beta-estradiol in MCF-7 cells by mitogen-activated protein kinase-dependent phosphorylation of ELK-1. J Cell Biochem 93: 1063-1074.
29. Quinones A, Dobberstein KU, Rainov NG (2003) The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci 72: 2975-2992.
30. Liu X, Kelm RJ Jr., Strauch AR (2009) Transforming growth factor beta1- mediated activation of the smooth muscle alpha-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-alpha via mitogen-activated protein kinase kinase 1-dependent induction of the Egr-1 transcriptional repressor. Mol Biol Cell 20: 2174-2185.
31. Lim CP, Jain N, Cao X (1998) Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 16: 2915-2926.
32. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM (1999) Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 154: 937-944.
33. Schwachtgen JL, Houston P, Campbell C, Sukhatme V, Braddock M (1998) Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. J Clin Invest 101: 2540-2549.
34. Chang Y, Lee HH, Chen YT, Lu J, Wu SY, et al. (2006) Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J Virol 80: 7748-7755.
35. Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM (2010) EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 29: 4352-4361.
36. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
37. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, et al. (1997) Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 3: 1339-1346.
38. Hamilton JW, McCaffrey J, Caron RM, Louis CA, Treadwell MD, et al. (1994) Genotoxic chemical carcinogens target inducible genes in vivo. Ann N Y Acad Sci 726: 343-345.
39. Mazar AP (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 14: 5649-5655.
40. Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, et al. (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53: 3109-3117.
41. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, et al. (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20: 421-430.
42. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, et al. (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92: 77-91.
43. de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, et al. (2005) Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. Febs J 272: 3572-3582.
44. Dass CR, Nadesapillai AP, Robin D, Howard ML, Fisher JL, et al. (2005) Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 22: 643-652.
45. Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36.
46. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, et al. (1996) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 271: 23176-23184.
47. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, et al. (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143.
48. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811.
49. Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, et al. (2009) Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets 10: 937-949.
50. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397.
51. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137.
52. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
53. Henley DB, May PC, Dean RA, Siemers ER (2009) Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 10: 1657-1664.
54. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, et al. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66: 48-54.
55. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65: 1031-1038.
56. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, et al. (2009) Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957-1965.